Experts are excitedly examining retatrutide, a promising treatment developed by Eli Lilly, as a potential step in body reduction . Different than many earlier approaches, retatrutide is a twin-action agonist targeting simultaneously GLP-1 and GIP, substances that affect hunger and blood sugar contr